Micardis Prophylaxis Should Have Only Limited Patient Population, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
High-risk patients intolerant of ramipril need an alternative to the angiotensin-converting enzyme inhibitor, FDA's cardio-renal advisory committee concludes.